The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.

Autor: Apolo AB; Center for Cancer Research, National Cancer Institute, Bethesda., Bellmunt J; Dana Farber Cancer Institute, Boston., Cordes L; Center for Cancer Research, National Cancer Institute, Bethesda., Gupta S; Cleveland Clinic Taussig Cancer Institute, Cleveland, USA., Powles T; Barts Cancer Centre, London, UK. Electronic address: thomas.powles1@nhs.net., Rosenberg JE; Memorial Sloan Kettering, New York, USA., Van Der Heijden MS; National Cancer Institute (NKI), Amsterdam, the Netherlands.
Jazyk: angličtina
Zdroj: ESMO open [ESMO Open] 2024 Sep; Vol. 9 (9), pp. 103725. Date of Electronic Publication: 2024 Sep 05.
DOI: 10.1016/j.esmoop.2024.103725
Databáze: MEDLINE